Showing 801-810 of 1539 results for "".
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- MELA Sciences Rings in Melanoma Monday with NASDAQ Opening Bellhttps://practicaldermatology.com/news/20120507-mela_sciences_rings_in_melanoma_monday_with_nasdaq_opening_bell/2459807/MELA Sciences, Inc. (NASDAQ: MELA) is kicking off Melanoma/Skin Cancer Detection and Prevention Month by ringing the opening bell for NASDAQ Monday morning. Dr. Doris Day will ring
- Promiseb Complete Launches for Seborrheic Dermatitishttps://practicaldermatology.com/news/20120425-promiseb_complete_launches_for_seborrheic_dermatitis/2459814/Promiseb Complete, a new regimen for patients with seborrheic dermatitis (SD), is now available from Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories,. The line features Promiseb Topical Cream, a non-steroidal, prescription cream fo
- Andrew Weinstein Voted AAD President-Electhttps://practicaldermatology.com/news/Andrew-Weinstein-Voted-AAD-President-Elect/2471798/Andrew H. Weinstein, MD, MPH, FAAD, was voted president-elect of the American Academy of Dermatology (AAD), the organization announced. Dr. Weinstein will be joined by vice president-elect Thomas E. Rohrer, MD, FAAD. Newly elected members of the board of directors are Alina G. Bridges, DO,
- Benzene Update at AAD Discusses Both Regulations and Health Riskshttps://practicaldermatology.com/news/Benzene-Update-AAD-Discusses-Both-Regulations-Health-Risks/2471605/Christopher Bunick, MD, PhD, FAAD, made waves at the 2024 American Academy of Dermatology (AAD) Annual Meeting with his presentation about benzene in benzoyl peroxide (BPO) products for acne treatments. At the 2025 AAD Annual Meeting in Orlando, Florida, Dr. Bunick provided an update on the resea
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- 2% Medicare Payment Increase Could Be Imminenthttps://practicaldermatology.com/news/2-Medicare-Payment-Increase-Could-Be-Imminent/2471172/A 2% payment increase for physicians from Medicare appears close after American Academy of Dermatology (AAD) president Seemal Desai, MD, FAAD, attended a congressional session on February 11. “This bill has so much momentum that we are finally on the cusp,” Dr. Desai said during an AAD upd
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.